CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell
ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons.
Thus, we supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and
less relapses would occur in B-ALL or NHL. In this prospective phase 2 clinical trial, we aim
to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in
relapsed/refractory B-ALL or Large B cell lymphoma.